CRP and enthesitis: Of the 8 secukinumab non-responders, 6/8 had improvement in TJC, 6/8 had improvement in SJC with 3 having complete resolution, 4/4 had complete resolution in dactylitis, 2/2 had complete resolution in enthesitis, 1/1 had improvement in BASDAI, 6/6 had improvement in psoriasis with 1 having complete clearance, and 2/6 had > 5 improvement in their CRP level.